Caribou Biosciences (CRBU) Equity Average (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Equity Average data on file, last reported at $112.1 million in Q1 2026.

• Quarterly Equity Average fell 52.32% year-over-year to $112.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $112.1 million (down 52.32% YoY) and the FY2025 annual result came in at $187.6 million, down 39.63% from the prior year.
• Equity Average declined to $112.1 million in Q1 2026 per CRBU's latest filing, from $132.0 million in the prior quarter.
• Across five years, Equity Average topped out at $383.3 million in Q4 2023 and bottomed at $112.1 million in Q1 2026.
• The 5-year median for Equity Average is $295.8 million (2024), against an average of $278.8 million.
• The widest annual swing landed in 2022, when Equity Average jumped 1384.75%; it then slumped 52.32% in 2026.
• Tracing CRBU's Equity Average over 5 years: stood at $312.5 million in 2022, then grew by 22.67% to $383.3 million in 2023, then tumbled by 30.33% to $267.1 million in 2024, then plunged by 50.57% to $132.0 million in 2025, then retreated by 15.08% to $112.1 million in 2026.
• Per Business Quant, the three latest CRBU Equity Average figures stand at $112.1 million (Q1 2026), $132.0 million (Q4 2025), and $154.0 million (Q3 2025).

Peer Comparison